Search
SOLACI Congress
HomeESC 2020Pharmacology

Pharmacology

View Category
Acute coronary syndromes

ESC 2020 | Ticagrelor Might Increase Bleeding and Mortality in the Elderly

Ticagrelor compared against clopidogrel produces more bleeding and also more deaths in patients over 80 recently undergoing...
solaci -
Learn More
Other

ESC 2020 | Antihypertensive Therapy Reduces Events Regardless of BP Levels or Risk

Antihypertensive therapy reduces the risk of cardiovascular events even in patients with no history of heart disease...
solaci -
Learn More
Antithrombotic Anticoagulants

ESC 2020 | Rivaroxaban Might Reduce Cardiac Cerebral and Peripheral Events

Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in...
solaci -
Learn More
Chronic Ischemic cardiopathy

ESC 2020 | More Evidence on Colchicine for Chronic Ischemic Heart Disease

According to this new study, colchicine offers some benefit to patients with chronic ischemic heart disease. Similar...
solaci -
Learn More
Other

ESC 2020 | Dapagliflozin in Kidney Failure: The Drug Continues to Conquer Other Territories

The DAPA-CKD trial has shown dapagliflozin, a SGLT2 receptor inhibitor, improves function, and reduces cardiovascular events and...
solaci -
Learn More
Antiplatelet

ESC 2020 | Against the Grain, ASA Monotherapy Appears Superior after TAVR

After TAVR, patients with no anticoagulation indication are favored by monotherapy with aspirin (ASA) vs. dual antiaggregation...
solaci -
Learn More
Other

ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality

Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in...
solaci -
Learn More
Other

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

Dr. Carlos Fava - 0
This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Dr. Omar Tupayachi - 0
Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

Institutional News

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy